PT  - JOURNAL ARTICLE
AU  - Eleonora Rotondo
AU  - Alessandro Graziosi
AU  - Vincenzo Di Stefano
AU  - Angelika Anna Mohn
TI  - Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis
AID  - 10.1136/bcr-2018-226687
DP  - 2018 Nov 01
TA  - BMJ Case Reports
PG  - e226687
VI  - 11
IP  - 1
4099  - http://casereports.bmj.com/content/11/1/e226687.short
4100  - http://casereports.bmj.com/content/11/1/e226687.full
SO  - BMJ Case Reports2018 Nov 01; 11
AB  - Multiple sclerosis (MS) is a chronic inflammatory disease with demyelination of the central nervous system. High-dosage corticosteroids are the first-line therapy in the acute relapsing of MS. We report a case of severe high-dose methylprednisolone-induced acute hepatitis in a patient with a new diagnosis of MS. A 16-year-old girl was admitted for urticaria, angioedema, nausea and vomiting a month later she had been diagnosed with MS and treated with high-dosage methylprednisolone. Laboratory investigations showed hepatic insufficiency with grossly elevated liver enzymes. A liver biopsy showed focal centrilobular hepatocyte necrosis with interface hepatitis. Methylprednisolone-induced hepatotoxicity can confuse the clinical picture of patients with MS and complicate the differential diagnosis. We believe that each specialist should know it and monitor patients with MS taking high doses of methylprednisolone. As there is no screening model that predicts idiosyncratic hepatotoxicity, we promote screening for potential liver injury following pulse steroid therapy.